Given the pivotal role of IL‐17A in bolstering the host's defense against extracellular bacterial and fungal infections, its microbial regulation may be a significant factor contributing to the clinical trial failures of IL‐17A‐targeting monoclonal antibodies.1, 3. The gene discussed is IL17A; the disease is fungal infectious disease.